晚睡型抑郁患者报告SSRI疗效较差:基于自我评定的调查
澳大利亚抑郁症遗传学研究(n=15,108)通过问卷记录10种抗抑郁药使用体验,并计算时辰型多基因评分。结果显示,自我评定越偏晚睡型,艾司西酞普兰、西酞普兰、氟西汀、舍曲林和去甲文拉法辛的疗效越差,副作用越多,但与症状改善持续时间或停药无关。时辰型多基因评分仅与自杀意念和自杀未遂相关。
要点
- 自我评定晚睡型与5种抗抑郁药疗效较差及副作用增多相关。
- 晚睡型与症状改善持续时间或因副作用停药无关。
- 多基因评分仅与自杀意念/未遂相关,提示表型失调驱动药物反应。
核心结论
- 自我评定晚睡型与多种SSRI及去甲文拉法辛疗效较差和副作用增多相关。
- 时辰型多基因评分仅与自杀想法和自杀未遂相关,与药物疗效无关。
研究设计与样本
- 澳大利亚抑郁症遗传学研究纳入15,108名参与者(75%女性,18-90岁,68%至少一种其他终生诊断),通过问卷记录10种抗抑郁药使用体验并使用简版早晚问卷评估时辰型。
- 计算时辰型多基因评分,采用年龄和性别校正回归模型(Bonferroni校正)分析抗抑郁药变量与自我评定及遗传时辰型的关联。
主要发现
- 时辰型多基因评分解释自我评定时辰型4%的方差(r=0.21)。
- 自我评定晚睡型越高,艾司西酞普兰疗效越差(OR=1.04;95%CI 1.02-1.06;p=.000035)。
- 自我评定晚睡型越高,西酞普兰(OR=1.03;95%CI 1.01-1.05;p=.004)、氟西汀(OR=1.03;95%CI 1.01-1.05;p=.001)、舍曲林(OR=1.02;95%CI 1.01-1.04;p=.0008)和去甲文拉法辛(OR=1.03;95%CI 1.01-1.05;p=.004)疗效越差。
- 自我评定晚睡型与80%记录的副作用增多相关(ORs=0.93-0.98),最常见为入睡困难。
- 自我评定时辰型与症状改善持续时间或停药无关;多基因评分仅与自杀想法和自杀未遂相关。
临床怎么用
- 对抑郁患者评估时辰型可能有助于预判SSRI疗效和副作用风险。
- 晚睡型患者使用艾司西酞普兰、西酞普兰、氟西汀、舍曲林或去甲文拉法辛时需关注疗效和入睡困难等副作用。
局限性
- 测量工具不完美,非控制条件下昼夜节律相位。
- 自我报告数据可能存在回忆偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preliminary evidence suggests that evening chronotype is related to poorer efficacy of selective serotonin reuptake inhibitors. It is unknown whether this is specific to particular medications, self-rated chronotype, or efficacy. METHODS: In the Australian Genetics of Depression Study (n = 15,108; 75% women; 18-90 years; 68% with ≥1 other lifetime diagnosis), a survey recorded experiences with 10 antidepressants, and the reduced Morningness-Eveningness Questionnaire was used to estimate chronotype. A chronotype polygenic score was calculated. Age- and sex-adjusted regression models (Bonferroni-corrected) estimated associations among antidepressant variables (how well the antidepressant worked [efficacy], duration of symptom improvement, side effects, discontinuation due to side effects) and self-rated and genetic chronotypes. RESULTS: The chronotype polygenic score explained 4% of the variance in self-rated chronotype (r = 0.21). Higher self-rated eveningness was associated with poorer efficacy of escitalopram (odds ratio [OR] = 1.04; 95% CI, 1.02 to 1.06; p = .000035), citalopram (OR = 1.03; 95% CI, 1.01 to 1.05; p = .004), fluoxetine (OR = 1.03; 95% CI, 1.01 to 1.05; p = .001), sertraline (OR = 1.02; 95% CI, 1.01 to 1.04; p = .0008), and desvenlafaxine (OR = 1.03; 95% CI, 1.01 to 1.05; p = .004), and a profile of increased side effects (80% of those recorded; ORs = 0.93-0.98), with difficulty getting to sleep the most common. Self-rated chronotype was unrelated to duration of improvement or discontinuation. The chronotype polygenic score was only associated with suicidal thoughts and attempted suicide (self-reported). While our measures are imperfect, and not of circadian phase under controlled conditions, the model coefficients suggest that dysregulation of the phenotypic chronotype relative to its genetic proxy drove relationships with antidepressant outcomes. CONCLUSIONS: The idea that variation in circadian factors influences response to antidepressants was supported and encourages exploration of circadian mechanisms of depressive disorders and antidepressant treatments.
引用
- Crouse JJ, Park SH, Byrne EM, et al. Evening Chronotypes With Depression Report Poorer Outcomes of Selective Serotonin Reuptake Inhibitors: A Survey-Based Study of Self-Ratings. Biol Psychiatry. 2024. PMID: 38185236. doi:10.1016/j.biopsych.2023.12.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。